CLOs on the Move

Enzyvant

www.enzyvant.com

 
Enzyvant is also advancing the development of RVT-802, an investigational tissue-based biologic therapy for the potential treatment of primary immune deficiency associated with complete DiGeorge Syndrome. RVT-802 has been granted orphan drug designation, Breakthrough Therapy designation, Regenerative Medicine Advanced Therapy designation, and pediatric rare disease designation by the U.S. Food and Drug Administration. Enzyvant anticipates a potential BLA filing for RVT-802 in the first half of 2018. Enzyvant plans to develop treatments for additional rare diseases with high unmet need.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.enzyvant.com
  • 90 Broadway Suite 204
    Cambridge, MA USA 02142
  • Phone: 617.704.9385

Executives

Name Title Contact Details
Tamara Joseph
General Counsel Profile

Similar Companies

Locus Biosciences

Locus Biosciences` novel approach to precision antimicrobials works by taking advantage of an immune system present in many bacteria called the CRISPR-Cas system. The CRISPR-Cas system protects bacteria from invaders such as viruses by creating a small strand of RNA called a CRISPR RNA, which matches a DNA sequence specific to a given invader. If the CRISPR RNA is matched to a complementary DNA sequence, the Cas proteins will cleave the invading DNA.

Lynxcom Partners

Lynxcom Partners is a Del Mar, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Strategic Partnerships

Strategic Partnerships, LLC is a Alexandria, VA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Kadmon

Kadmon is a fully integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of significant unmet medical need. We are developing product candidates within autoimmune and fibrotic diseases, oncology and genetic diseases. We leverage our multi-disciplinary research and clinical development team members, who prior to joining Kadmon had brought more than 15 drugs to market, to identify and pursue a diverse portfolio of novel product candidates, both through in-licensing products and employing our small molecule and biologics platforms. We utilize our advanced understanding of the molecular mechanisms of disease to establish development paths for disease areas where significant unmet medical needs exist.

Health Quality Council

Health Quality Council is a Saskatoon, SK-based company in the Healthcare, Pharmaceuticals, & Biotech sector.